In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

Roche’s Genentech was supposed to get a priority review for its combo using Tecentriq and Avastin plus chemo in frontline lung cancer cases, with a deadline on the FDA’s decision set for Wednesday. And usually, that means a green light is on its way sooner rather than later.